Related Experiment Video
Updated: May 9, 2026
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
[Ways to personalized medicine for gastric cancer]
1Institut für Pathologie, Christian-Albrechts-Universität Kiel, Arnold-Heller-Strasse 3/14, Kiel, Germany. christoph.roecken@uk-sh.de
Abstract:
Gastric cancer is the fourth most common tumor and the second most common cause of cancer-related deaths in the world. Approximately 70 % of the patients already have lymph node metastases at the time of the diagnosis leading to a median overall survival time of 16.7 months. Complete resection of the primary tumor with D2 lymphadenectomy offers the only chance of cure in the early stages of the disease. Survival of more locally advanced gastric cancer was improved by the introduction of perioperative, adjuvant and palliative chemotherapy of gastric cancer; however, the identification of novel predictive and diagnostic targets is urgently needed. Our own studies on gastric cancer biology identified several putative tumor biologically relevant G-protein-coupled receptors (e.g. AT1R, AT2R, CXCR4, FZD7, LGR4, LGR5, LGR6). Some of these receptors are also putative stem cell markers and may serve as future targets of an individualized therapy of gastric cancer.
Insights
Gastric cancer, a leading cause of death, requires new therapeutic targets. Researchers identified G-protein-coupled receptors as potential biomarkers for individualized gastric cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Gastroenterology
Context:
- Gastric cancer is a significant global health burden, ranking as the fourth most common tumor and second leading cause of cancer mortality.
- High rates of lymph node metastasis at diagnosis contribute to poor prognoses, with a median overall survival of 16.7 months.
- While surgical resection and chemotherapy have improved survival, novel predictive and diagnostic targets are crucial for advancing gastric cancer treatment.
Purpose:
- To identify novel molecular targets for gastric cancer therapy.
- To explore the role of specific G-protein-coupled receptors (GPCRs) in gastric cancer biology.
- To investigate GPCRs as potential biomarkers for individualized gastric cancer treatment strategies.
Summary:
- Studies identified several G-protein-coupled receptors (GPCRs), including AT1R, AT2R, CXCR4, FZD7, LGR4, LGR5, and LGR6, as biologically relevant in gastric cancer.
- Some of these GPCRs are also implicated as stem cell markers.
- These findings suggest GPCRs as promising targets for developing personalized therapies for gastric cancer.
Impact:
- The identification of GPCRs offers potential for developing targeted therapies to improve patient outcomes in gastric cancer.
- These receptors may serve as valuable biomarkers for predicting treatment response and guiding individualized therapeutic approaches.
- This research contributes to the ongoing effort to find novel strategies for combating gastric cancer.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:18Cancer